medecolМедицина и экологияMedicine and ecology2305-60452305-6053Карагандинский медицинский университет10.59598/ME-2305-6045-2024-112-3-75-81medecol-753Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEРоль и прогностическое значение гена интерлейкина 2 при множественной миеломеThe role and prognostic value of the interleukin 2 gene at multiple myelomaМахамадалиеваГ. З.MakhamadaliyevaG. Z.

Гулчехра Зухридиновна Махамадалиева – PhD, главный гематолог Республики Узбекистан, заведующая отделением трансплантации

г. Ташкент, Чиланзарский район, ул. Арнасай, 16/1А

Gulchehra Zukhridinovna Makhamadaliyeva – PhD, Chief Hematologist of the Republic of Uzbekistan, Head of the Transplantation Department

Tashkent city, Chilanzar district, Arnasai str., 16/1A

kuzieva79@mail.ruКаюмовА. А.KayumovA. A.

г. Ташкент, Чиланзарский район, ул. Арнасай, 16/1А

Tashkent city, Chilanzar district, Arnasai str., 16/1A

АхрароваН. К.AkhrarovaN. K.

г. Ташкент, Чиланзарский район, ул. Арнасай, 16/1А

Tashkent city, Chilanzar district, Arnasai str., 16/1A

КаххароваН. Х.KakhkharovaN. H.

г. Ташкент, Чиланзарский район, ул. Арнасай, 16/1А

Tashkent city, Chilanzar district, Arnasai str., 16/1A

Республиканский специализированный научно-практический медицинский центр гематологии Республики УзбекистанУзбекистанRepublican Specialized Scientific and Practical Medical Center of Hematology of the Republic of UzbekistanUzbekistan202424102024037581Copyright © Махамадалиева Г.З., Каюмов А.А., Ахрарова Н.К., Каххарова Н.Х., 20242024Махамадалиева Г.З., Каюмов А.А., Ахрарова Н.К., Каххарова Н.Х.Makhamadaliyeva G.Z., Kayumov A.A., Akhrarova N.K., Kakhkharova N.H.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://medecol.qmu.kz/jour/article/view/753

Цель. Определить связь полиморфного локуса генетического маркера IL2 (Т-330G) с риском осложненного течения множественной миеломы.Материалы и методы. Молекулярный анализ гена IL2 (Т-330G) проводился в лаборатории молекулярной генетики, цитогенетики и FISH при Республиканском специализированном научно-практическом медицинском центре гематологии Республики Узбекистан (г. Ташкент). Были обследованы 101 пациент в возрасте от 34 до 72 лет с достоверно установленным диагнозом множественной миеломы. Полиморфизм IL2 (Т-330G) генотипирован методом ПЦР в реальном времени с использованием праймеров компании «Литех» (Россия) при помощи термоциклера «Applied Biosystems» (США).Результаты и обсуждение. Обнаружено повышение риска осложненного течения множественной миеломы по сравнению со здоровыми лицами в 1.6 раза среди носителей мутантного аллеля G (χ2=4.3; р=0.05). Выявлены статистически достоверные различия между неблагоприятными локусами в группе больных с сочетанными осложнениями множественной миеломы по сравнению с контролем.Bыводы. Риск развития множественной миеломы по сравнению со здоровыми лицами в 1.6 раза выше среди носителей мутантного аллеля G (χ2=4.3; р=0.05) по полиморфизму гена IL2 (Т-330G). Наряду с этим статистически значимая связь установлена между неблагоприятными локусами (G и G/G) с увеличением в 2.5 (χ2=9.4; р=0.01) и 3.5 раза (χ2=5.3; р=0.03) риска развития множественной миеломы, осложненной плазмацитомой в сочетании с нефропатией.

Aim of the study. To determine the relationship of the polymorphic locus of the IL2 genetic marker (T-330G) with the risk of complicated course of multiple myeloma.Materials and methods. The molecular analysis of the IL2 (T-330G) gene was carried out in the laboratory of Molecular Genetics, cytogenetics and FISH at the Republican Specialized Scientific and Practical Medical Center of Hematology of the Republic of Uzbekistan (Tashkent city). 101 patients aged 34 to 72 years with a reliably established diagnosis of multiple myeloma were examined. IL2 polymorphism (T-330G) was genotyped by real-time PCR using primers from Litech (Russia) using an Applied Biosystems thermal cycler (USA).Results and discussion. An increased risk of complicated course of multiple myeloma compared with healthy individuals was found to be 1.6 times higher among carriers of the mutant G allele (χ2=4.3; p=0.05). Statistically significant differences between unfavorable loci in the group of patients with combined complications of multiple myeloma compared with the control were revealed.Conclusions. The risk of developing multiple myeloma compared with healthy individuals is 1.6 times higher among carriers of the mutant G allele (χ2=4.3; p=0.05) according to the polymorphism of the IL2 gene (T-330G). Along with this, a statistically significant relationship was established between unfavorable loci (G and G/G) with an increase of 2.5 (χ2=9.4; p=0.01) and 3.5 times (χ2=5.3; p=0.03) the risk of developing multiple myeloma complicated by plasmacytoma in combination with nephropathy.  

множественная миеломамолекулярная генетикаполиморфизминтерлейкин 2multiple myelomamolecular geneticspolymorphisminterleukin 2ReferencesБессмельцев С. С. Множественная миелома: диагностика и терапия (часть 2) //Вестник гематологии. – 2022. – №18 (3). – С. 4-31.Bessmel'cev S. S. Mnozhestvennaja mieloma: diagnostika i terapija (chast' 2) //Vestnik gematologii. – 2022. – №18 (3). – S. 4-31.Множественная миелома. Клинические рекомендации /Л. П. Менделеева, О. М. Вотякова, И. Г. Рехтина и др. //Современная онкология. – 2020. – №22 (4). – С. 6-28.Mnozhestvennaja mieloma. Klinicheskie rekomendacii /L. P. Mendeleeva, O. M. Votjakova, I. G. Rehtina i dr. //Sovremennaja onkologija. – 2020. – №22 (4). – S. 6-28.Allegra A. Lymphocyte subsets and inflammatory cytokines of monoclonal gammopathy of undetermined significance and multiple myeloma // International Journal of Molecular Sciences. – 2019. – V. 20, №11. – P. 2822.Allegra A. Lymphocyte subsets and inflammatory cytokines of monoclonal gammopathy of undetermined significance and multiple myeloma // International Journal of Molecular Sciences. – 2019. – V. 20, №11. – P. 2822.Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence /K. Misund, O. Hofste, D. Bruinink et al. //Leukemia. – 2022. – V. 36 (7). – Pp. 1887-1897.Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence /K. Misund, O. Hofste, D. Bruinink et al. //Leukemia. – 2022. – V. 36 (7). – Pp. 1887-1897.Epidemiology of multiple myeloma in 17 Latin American countries: An update /M. P. Curado, M. M. Oliveira, D. R. M. Silva, D. L. B. Souza //Cancer Med. – 2018. – V. 7. – P. 2101-2108.Epidemiology of multiple myeloma in 17 Latin American countries: An update /M. P. Curado, M. M. Oliveira, D. R. M. Silva, D. L. B. Souza //Cancer Med. – 2018. – V. 7. – P. 2101-2108.Interleukins and their signaling pathways in the Reactome biological pathway database /S. Jupe, K. Ray, C. D. Roca et al. //J. Allergy. Clin. Immunol. – 2018. – V. 141. – Pp. 1411-1416.Interleukins and their signaling pathways in the Reactome biological pathway database /S. Jupe, K. Ray, C. D. Roca et al. //J. Allergy. Clin. Immunol. – 2018. – V. 141. – Pp. 1411-1416.Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and riskadapted maintenance apрroach in newly diagnosed multiple myeloma /N. Joseph, J. Kaufman, M. Dhodapkar et al. //J. Clin. Oncol. – 2020. – V. 38 (17). – Pp. 1928-1937.Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and riskadapted maintenance aprroach in newly diagnosed multiple myeloma /N. Joseph, J. Kaufman, M. Dhodapkar et al. //J. Clin. Oncol. – 2020. – V. 38 (17). – Pp. 1928-1937.Musolino C. Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma //Mediators of inflammation. – 2017. – V. 2017. – 1852517.Musolino C. Inflammatory and anti-inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma //Mediators of inflammation. – 2017. – V. 2017. – 1852517.Nazarova E. L. Molecular features of bortezomib-induced neuropathy in patients with multiple myeloma //Russian journal of hematology and transfusiology. – 2019. – V. 64, №1. – Pp. 79-89.Nazarova E. L. Molecular features of bortezomib-induced neuropathy in patients with multiple myeloma //Russian journal of hematology and transfusiology. – 2019. – V. 64, №1. – Pp. 79-89.Nazarova E. L. Prognostic Value of Genetic Markers for Efficacy Estimation of Induction Treatment Including Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients //Clinical oncohematology. – 2018. – V. 11 (1). – P. 54-69.Nazarova E. L. Prognostic Value of Genetic Markers for Efficacy Estimation of Induction Treatment Including Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients //Clinical oncohematology. – 2018. – V. 11 (1). – P. 54-69.Potential clinical application of genomics in multiple myeloma /C. Y. Soekojo, S. de Mel, M. Ooi et al. //Int. J. Mol. Sci. – 2018. – V. 9. – E1721.Potential clinical application of genomics in multiple myeloma /C. Y. Soekojo, S. de Mel, M. Ooi et al. //Int. J. Mol. Sci. – 2018. – V. 9. – E1721.Semochkin S. V. Mechanisms of action of immunomodulatory drugs — from teratogenicity to treatment of multiple myeloma //Russian Journal of Hematology and Transfusiology. – 2022. – V. 67 (2). – Pp. 240-260.Semochkin S. V. Mechanisms of action of immunomodulatory drugs — from teratogenicity to treatment of multiple myeloma //Russian Journal of Hematology and Transfusiology. – 2022. – V. 67 (2). – Pp. 240-260.Serin I. Effect of interleukin-2 (IL-2) polymorphisms on multiple myeloma: IL-2RA rs2104286, IL-2 rs2069762 and rs2069763 polymorphisms //Cytokine. – 2023. – V. 172. – 156401.Serin I. Effect of interleukin-2 (IL-2) polymorphisms on multiple myeloma: IL-2RA rs2104286, IL-2 rs2069762 and rs2069763 polymorphisms //Cytokine. – 2023. – V. 172. – 156401.Shahzad M. N. Association between interleukin gene polymorphisms and multiple myeloma susceptibility //Molecular and Clinical Oncology. – 2020. – V. 12, №3. – Pp. 212-224.Shahzad M. N. Association between interleukin gene polymorphisms and multiple myeloma susceptibility //Molecular and Clinical Oncology. – 2020. – V. 12, №3. – Pp. 212-224.Sun H. Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma //Journal for immunotherapy of cancer. – 2021. – V. 9, №7. – e002958.Sun H. Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma //Journal for immunotherapy of cancer. – 2021. – V. 9, №7. – e002958.Svitina S. P. Polymorphism of Interleukins and Tumor Necrosis Factor α Genes in Multiple Myeloma Patients with Autologous Hematopoietic Stem Cell Transplantation //Clinical oncohematology. – 2021. – V. 14 (3). – P. 340-346.Svitina S. P. Polymorphism of Interleukins and Tumor Necrosis Factor α Genes in Multiple Myeloma Patients with Autologous Hematopoietic Stem Cell Transplantation //Clinical oncohematology. – 2021. – V. 14 (3). – P. 340-346.Szudy-Szczyrek A. Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients //Oncotarget. – 2018. – V. 9, №35. – P. 24054.Szudy-Szczyrek A. Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients //Oncotarget. – 2018. – V. 9, №35. – P. 24054.Valkovic T. Multiple myeloma index for risk of infection /T. Valkovic, V. Gacic, A. Nacinovic-Duletic //J. Cancer. – 2018. – V. 9. – Pp. 2211-2214.Valkovic T. Multiple myeloma index for risk of infection /T. Valkovic, V. Gacic, A. Nacinovic-Duletic //J. Cancer. – 2018. – V. 9. – Pp. 2211-2214.

The authors declare that there are no conflicts of interest present.